Company Overview of Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes in the United States. The company’s product candidates include FPA008, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor, as well as conducts Phase I clinical trials for the treatment of rheumatoid arthritis. Its product candidates also comprise FPA144, an antibody that inhibits fibroblast grow...
Two Corporate Drive
South San Francisco, CA 94080
Founded in 2001
Key Executives for Five Prime Therapeutics, Inc.
Founder, Chairman, Chief Executive Officer and President
Total Annual Compensation: $525.0K
Chief Operating Officer and Director
Total Annual Compensation: $383.5K
Chief Strategy Officer and Secretary
Total Annual Compensation: $358.5K
Compensation as of Fiscal Year 2015.
Five Prime Therapeutics, Inc. Key Developments
Five Prime Therapeutics, Inc. Initiates Phase 1b Portion of Trial Evaluating the Immunotherapy Combination of Cabiralizumab (Fpa008) and Opdivo (Nivolumab) in Multiple Tumor Types
Oct 4 16
Five Prime Therapeutics, Inc. announced that it has initiated the Phase 1b portion of the clinical trial evaluating the immunotherapy combination of cabiralizumab (FPA008), Five Prime's investigational monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF1R), with OPDIVO® (nivolumab), Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, in multiple tumor types. Five Prime initiated the Phase 1a/1b trial, which is expected to enroll approximately 280 patients, in September 2015. During Phase 1a, Five Prime evaluated the safety, pharmacokinetics and biomarkers of escalating doses of cabiralizumab as a monotherapy, as well as in combination with the approved 3 mg/kg dose of nivolumab. Five Prime will continue to run the Phase 1b portion of the trial and will evaluate the safety, tolerability and preliminary efficacy of the selected dose of cabiralizumab in combination with nivolumab for the treatment of advanced solid tumors, including but not limited to non-small cell lung cancer, squamous cell carcinoma of the head and neck, pancreatic cancer, glioblastoma, renal cell carcinoma and ovarian cancer.
Five Prime Therapeutics, Inc. Promotes Aron M. Knickerbocker to the Position of Chief Operating Officer and its Principal Operating Officer
Sep 14 16
On September 8, 2016, the Board of Directors of Five Prime Therapeutics, Inc. promoted Aron M. Knickerbocker, FivePrime's previous Chief Business Officer, to the position of Chief Operating Officer and appointed Mr. Knickerbocker as FivePrime's principal operating officer, effective immediately.
Five Prime Therapeutics, Inc. Presents at The 2016 Morgan Stanley Global Healthcare Conference, Sep-13-2016 04:40 PM
Sep 6 16
Five Prime Therapeutics, Inc. Presents at The 2016 Morgan Stanley Global Healthcare Conference, Sep-13-2016 04:40 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Lewis T. Williams, Founder, Chairman, Chief Executive Officer and President.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|